

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H1 2018

https://marketpublishers.com/r/M681C492A44EN.html

Date: March 2018

Pages: 38

Price: US\$ 3,500.00 (Single User License)

ID: M681C492A44EN

Abstracts

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Myc Proto Oncogene Protein - Pipeline Review, H1 2018'; Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases.

It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

The report 'Myc Proto Oncogene Protein - Pipeline Review, H1 2018' outlays



comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 6 and 4 respectively.

Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Hematological Tumor, Lymphoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chondrosarcoma, Glioblastoma Multiforme (GBM), Leukemias, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer and Pancreatic Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and



collaboration details & other developmental activities

The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects

The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics



Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop

Helix Protein 39 or MYC) - Overview

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop

Helix Protein 39 or MYC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop

Helix Protein 39 or MYC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop

Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development

Peptomyc SL

Phylogica Ltd

Sorrento Therapeutics Inc

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop

Helix Protein 39 or MYC) - Drug Profiles

BGA-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-4000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galarmin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit c-Myc for Solid Tumors and Hematological Malignancies

- Drug Profile

Product Description



Mechanism Of Action

R&D Progress

OMO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMO-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cMyc for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug

Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile

Product Description

Mechanism Of Action



R&D Progress

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer

Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Peptomyc SL, H1 2018

Pipeline by Phylogica Ltd, H1 2018

Pipeline by Sorrento Therapeutics Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Peptomyc SL Phylogica Ltd Sorrento Therapeutics Inc



I would like to order

Product name: Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix

Protein 39 or MYC) - Pipeline Review, H1 2018

Product link: https://marketpublishers.com/r/M681C492A44EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M681C492A44EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$

